Expression of laminin β2: A novel marker of hypoxia in pituitary adenomas

Endocrine Pathology

Volumn 17, Issue 3, 2006, Pages 251-261

  Bao, Yijun ^a,b   Yoshida, Daizo ^a   Morimoto, Daijiro ^a   Teramoto, Akira ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Hypoxia; Invasion; Laminin chains; Macroadenoma; Pituitary adenomas; Pituitary apoplexy

Indexed keywords

LAMININ; LAMININ BETA1; LAMININ BETA2; LAMININ BETA3; UNCLASSIFIED DRUG; LAMININ S; TUMOR MARKER;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPHYSIS ADENOMA; HYPOXIA; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME; WESTERN BLOTTING; ADENOMA; ADOLESCENT; BIOSYNTHESIS; CELL HYPOXIA; HYPOPHYSIS TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ADENOMA; ADOLESCENT; ADULT; AGED; BLOTTING, WESTERN; CELL HYPOXIA; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LAMININ; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33847155445     PISSN: 10463976     EISSN: None     Source Type: Journal    
DOI: 10.1385/EP:17:3:251     Document Type: Article

References (40)

1. Yoshida D, Kim K, Yamazaki M, Teramoto A. Expression of hypoxia-inducible factor 1alpha and cathepsin D in pituitary adenomas. Endocr Pathol 16(2):123-131, 2005.
2. Yoshida D, Kim K, Noha M, Teramoto A. Anti-apoptotic action by hypoxia inducible factor 1-alpha in human pituitary adenoma cell line, HP-75 in hypoxic condition. J Neurooncol 78(3):217-225, 2006
3. Schipani E. Hypoxia and HIF-1alpha in chondrogenesis. Semin Cell Dev Biol 16(4-5):539-546, 2005.
4. Weinmann M, Belka C, Plasswilm L. Tumour hypoxia: impact on biology, prognosis and treatment of solid malignant tumours. Onkologie 27(1):83-90, 2004.
5. Subarsky P, Hill RP. The hypoxic tumour microenvironment and metastatic progression. Clin Exp Metastasis 20: 237-250, 2003.
6. Raghunand N, Gatenby RA, Gillies RJ. Microenvironmental and cellular consequences of altered blood flow in tumours. Br J Radiol 76 (Spec No 1):S11-22, 2003.
7. Viacava P, Gasperi M, Acerbi G, et al. Microvascular density and vascular endothelial growth factor expression in normal pituitary tissue and pituitary adenomas. J Endocrinol Invest 26(1):23-28, 2003.
8. Pinheiro MM, Cukiert A, Salgado LR, et al. Subclinical apoplexy in pituitary tumors. Arq Neuropsiquiatr 57(1):74-77, 1999.
9. Ahmadi J, North CM, Segall HD, Zee CS, Weiss MH. Cavernous sinus invasion by pituitary adenomas. AJNR 6:893-898, 1985.
10. Fahlbusch R, Buchfelder M. Transsphenoidal surgery of parasellar pituitary adenomas. Acta Neurochir (Wien) 92:93-99, 1988.
11. Oruckaptan HH, Senmevsim O, Ozcan OE, Ozgen T. Pituitary adenomas: results of 684 surgically treated patients and review of the literature. Surg Neurol 53(3):211-219, 2000.
12. Wolfsberger S, Kitz K, Wunderer J, et al. Multiregional sampling reveals a homogenous distribution of Ki-67 proliferation rate in pituitary adenomas. Acta Neurochir (Wien) 146(12):1323-1327, 2004.
13. Nishioka H, Haraoka J, Akada K. Growth potential of prolactinomas in men: is it really different from women? Surg Neurol 59(5):386-390, 2003.
14. Iuchi S, Saeki N, Uchino Y, et al. Cavernous sinus invasion and tumor proliferative potential of growth hormone-producing pituitary tumors. Endocr J 47 (Suppl):S77-79, 2000.
15. Onguru O, Scheithauer BW, Kovacs K, et al. Analysis of Cox-2 and thromboxane synthase expression in pituitary adenomas and carcinomas. Endocr Pathol 15(1):17-27, 2004.
16. Fukui S, Otani N, Nawashiro H, et al. Subcellular localization of basic fibroblast growth factor and fibroblast growth factor receptor 1 in pituitary adenomas. Brain Tumor Pathol 19(1): 23-29, 2002.
17. Knappe UJ, Hagel C, Lisboa BW, Wilczak W, Ludecke DK, Saeger W. Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue. Acta Neuropathol (Berl) 106(5):471-478, 2003.
18. Trouillas J, Daniel L, Guigard MP, et al. Polysialylated neural cell adhesion molecules expressed in human pituitary tumors and related to extrasellar invasion. J Neurosurg 98(5):1084-1093, 2003.
19. Takino H, Herman V, Weiss M, Melmed S. Purine-binding factor (nm23) gene expression in pituitary tumors: marker of adenoma invasiveness. J Clin Endocrinol Metab 80(5):1733-1738, 1995.
20. Selman WR, Laws ER, Scheithauer BW, Carpenter SM. The occurrence of dural invasion in pituitary adenoma. J Neurosurg 64:402-408, 1986.
21. Knosp E, Steiner E, Kitz K, Matula C. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33(4):610-617, 1993.
22. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49:6449-6465, 1989.
23. Kristof RA, Aliashkevich AF, Hans V, et al. The regional oxygen saturation of pituitary adenomas is lower than that of the pituitary gland: microspectrophotometric study with potential clinical implications. Neurosurgery 53(4):880-885, 2003.
24. Vaupel P, Kelleher DK, Hockel M. Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 28(suppl 8):29-35, 2001.
25. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93:266-276, 2001.
26. Hockel M, Vaupel P. Biological consequences of tumor hypoxia. Semin Oncol 28(suppl 8):36-41, 2001.
27. Vaupel P, Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist 9(Suppl 5):4-9, 2004.
28. Subarsky P, Hill RP. The hypoxic tumour microenvironment and metastatic progression. Clin Exp Metastasis 20(3):237-250, 2003.
29. Munoz-Najar UM, Neurath KM, Vumbaca F, Claffey KP. Hypoxia stimulates breast carcinoma cell invasion through MT1-MMP and MMP-2 activation. Oncogene 25:2379-2392, 2006.
30. Matteucci E, Locati M, Desiderio MA. Hepatocyte growth factor enhances CXCR4 expression favoring breast cancer cell invasiveness. Exp Cell Res 310(1):176-185, 2005.
31. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16:4604-4613, 1996.
32. Kim K, Yoshida D, Teramoto A. Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in pituitary adenomas. Endocr Pathol 16(2):115-121, 2005.
33. Semple PL, Webb MK, de Villiers JC, Laws ER Jr. Pituitary apoplexy. Neurosurgery 56(1):65-72, 2005.
34. Mohr G, Hardy J. Hemorrhage, necrosis, and apoplexy in pituitary adenomas. Surg Neurol 18:181-189, 1982.
35. Randeva HP, Schoebel J, Byrnet J, Esiri M, Adams CB, Wass JA. Classical pituitary apoplexy: clinical features, management and outcome. Clin Endocrinol (Oxf ) 51:181-188, 1999.
36. Patarroyo M, Tryggvason K, Virtanen I. Laminin isoforms in tumor invasion, angiogenesis and metastasis. Semin Cancer Biol 12(3):197-207, 2002.
37. Aumailley M, Smyth N. The role of laminins in basement membrane function. J Anat 193:1-21, 1998.
38. Koshikawa N, Moriyama K, Takamura H, et al. Overexpression of laminin gamma2 chain monomer in invading gastric carcinoma cells. Cancer Res 59(21):5596-5601, 1999.
39. Lenander C, Habermann JK, Ost A, et al. Laminin-5 gamma 2 chain expression correlates with unfavorable prognosis in colon carcinomas. Anal Cell Pathol 22(4):201-209, 2001.
40. Fukushima Y, Ohnishi T, Arita N, Hayakawa T, Sekiguchi K. Integrin alpha3β1-mediated interaction with laminin-5 stimulates adhesion, migration and invasion of malignant glioma cells. Int J Cancer 76(1):63-72, 1998.